Skip to main content

Table 3 Operative results of propensity score–matched patients

From: Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score–matched cohort study

 

EOX group (n = 102)

US group (n = 102)

P

Clavien–Dindo grade, n (%)a

  

0.877

 0

12 (11.8)

13 (12.7)

 

 1

24 (23.5)

31 (30.4)

 

 2

40 (39.2)

41 (40.2)

 

 3a

17 (16.7)

11 (10.8)

 

 3b

2 (2.0)

2 (2.0)

 

 4a

3 (2.9)

2 (2.0)

 

 4b

2 (2.0)

1 (1.0)

 

 5

1 (1.0)

2 (2.0)

 

CCI, median (IQR)

22.6 (8.7–30.8)

22.6 (8.7–34.2)

0.959

Reoperation, n (%)

5 (4.9)

4 (3.9)

1.000

ICU admission, n (%)

17 (16.7)

7 (6.9)

0.030

ICU stay (days), median (IQR)b

3.0 (2.0–7.0)

3.0 (2.0–8.0)

0.871

Length of hospital stay (days), median (IQR)

8.0 (7.0–11.0)

9.0 (7.0–12.0)

0.258

Readmission, n (%)

11 (10.8)

9 (8.8)

0.638

30-day mortality, n (%)

1 (1.0)

2 (2.0)

1.000

90-day mortality, n (%)

1 (1.0)

3 (2.9)

0.621

  1. Abbreviations: EOX epirubicin, oxaliplatin, and capesitabine, US upfront surgery, IQR interquartile range, CCI comprehensive complication index, ICU intensive care unit
  2. aHighest complication grade
  3. bFor patients admitted to ICU